Technology

Nuclide Therapeutics is pioneering precision radionuclide therapies that directly target and destroy resistant cancer cells, offering a new treatment pathway following the failure of conventional therapies.

Urgent Need

Urgent Need

Despite major advances in precision medicine, therapy resistance continues to limit long-term survival in hard-to-treat cancers, such as lung cancer, and demands entirely new therapeutic approaches.

18 Million

18 million new cancer cases every year

8 Million

Deaths from therapy resistant cancer

Lung Cancer

The leading cause of cancer-related death worldwide

18 Million

18 million new cancer cases every year

8 Million

Deaths from therapy resistant cancer

Lung Cancer

The leading cause of cancer-related death worldwide

18 Million

18 million new cancer cases every year

8 Million

Deaths from therapy resistant cancer

Lung Cancer

The leading cause of cancer-related death worldwide

18 Million

18 million new cancer cases every year

8 Million

Deaths from therapy resistant cancer

Lung Cancer

The leading cause of cancer-related death worldwide

Our Approach

Our Approach

Our Approach

Precision radiotheranostics

Nuclide Therapeutics is developing a new generation of radiopharmaceuticals designed to precisely identify and destroy resistant cancer cells.

Diagnostic

Radionuclide

Therapeutic

Radionuclide

Small Molecule

Targeting Resistance

Biomarker

NTx Platform

NTx platform combines

• Diagnostic or therapeutic radionuclide.

• Small molecule that binds to a defined biomarker found in resistant tumours.

• Together, they form a single targeted compound that can both visualise and eliminate disease, known as a radiotheranostic.

• This dual-application architecture enables patient stratification, real-time monitoring, and individualised treatment.

Mechanism of action

• When intravenously injected, the radiotheranostic selectively binds to and binds a biomarker expressed on therapy-resistant cancer cells.

• By attaching a diagnostic radionuclide,  the theranostic lights up on a PET/SPECT scan, acting as a beacon to detect resistance.

• Switching to a therapeutic radionuclide specifically kills and eliminates the resistant cancer cells, leaving healthy tissues intact.

Diagnostic

Radionuclide

Therapeutic

Radionuclide

Small Molecule

Targeting Resistance

Biomarker

NTx Platform

NTx platform combines

• Diagnostic or therapeutic radionuclide.

• Small molecule that binds to a defined biomarker found in resistant tumours.

• Together, they form a single targeted compound that can both visualise and eliminate disease, known as a radiotheranostic.

• This dual-application architecture enables patient stratification, real-time monitoring, and individualised treatment.

Mechanism of action

• When intravenously injected, the radiotheranostic selectively binds to and binds a biomarker expressed on therapy-resistant cancer cells.

• By attaching a diagnostic radionuclide,  the theranostic lights up on a PET/SPECT scan, acting as a beacon to detect resistance.

• Switching to a therapeutic radionuclide specifically kills and eliminates the resistant cancer cells, leaving healthy tissues intact.

Diagnostic

Radionuclide

Therapeutic

Radionuclide

Small Molecule

Targeting Resistance

Biomarker

NTx Platform

NTx platform combines

• Diagnostic or therapeutic radionuclide.

• Small molecule that binds to a defined biomarker found in resistant tumours.

• Together, they form a single targeted compound that can both visualise and eliminate disease, known as a radiotheranostic.

• This dual-application architecture enables patient stratification, real-time monitoring, and individualised treatment.

Mechanism of action

• When intravenously injected, the radiotheranostic selectively binds to and binds a biomarker expressed on therapy-resistant cancer cells.

• By attaching a diagnostic radionuclide,  the theranostic lights up on a PET/SPECT scan, acting as a beacon to detect resistance.

• Switching to a therapeutic radionuclide specifically kills and eliminates the resistant cancer cells, leaving healthy tissues intact.

Diagnostic

Radionuclide

Therapeutic

Radionuclide

Small

Molecule

Targeting

Resistance

Biomarker

NTx Platform

NTx platform combines

• Diagnostic or therapeutic radionuclide.

• Small molecule that binds to a defined biomarker found in resistant tumours.

• Together, they form a single targeted compound that can both visualise and eliminate disease, known as a radiotheranostic.

• This dual-application architecture enables patient stratification, real-time monitoring, and individualised treatment.

Mechanism of action

• When intravenously injected, the radiotheranostic selectively binds to and binds a biomarker expressed on therapy-resistant cancer cells.

• By attaching a diagnostic radionuclide,  the theranostic lights up on a PET/SPECT scan, acting as a beacon to detect resistance.

• Switching to a therapeutic radionuclide specifically kills and eliminates the resistant cancer cells, leaving healthy tissues intact.

Combining diagnostic imaging and targeted therapy in a single molecule

1. Diagnostic phase

PET/SPECT imaging to locate resistant tumours

2. Therapeutic phase

Targeted radiotherapy

3. Follow up

Monitoring treatment response

1. Diagnostic phase

PET/SPECT imaging to locate resistant tumours

2. Therapeutic phase

Targeted radiotherapy

3. Follow up

Monitoring treatment response

1. Diagnostic phase

2. Therapeutic phase

3. Follow up

PET/SPECT imaging to locate resistant tumours

Targeted radiotherapy

Monitoring treatment response

1. Diagnostic phase

2. Therapeutic phase

3. Follow up

PET/SPECT imaging to locate resistant tumours

Targeted radiotherapy

Monitoring treatment response

1. Diagnostic phase

2. Therapeutic phase

3. Follow up

PET/SPECT imaging to locate resistant tumours

Targeted radiotherapy

Monitoring treatment response

NTx Impact

Our technology addresses cancers that do not respond to existing therapies, aiming to make radiopharmaceuticals a mainstay of precision oncology.

By uniting nuclear medicine with biotechnology, Nuclide Therapeutics is working to transform therapy-resistant cancers into treatable diseases.

Connect with us

Email us and keep updated on our clinical trial and pipeline development on LinkedIn.

Connect with us

Email us and keep updated on our clinical trial and pipeline development on LinkedIn.

Connect with us

Email us and keep updated on our clinical trial and pipeline development on LinkedIn.

Multi colour gradient with abstract wave form

© 2025 Nuclide Therapeutics, All rights reserved

Privacy Policy

Cookie Policy

Multi colour gradient with abstract wave form

© 2025 Nuclide Therapeutics, All rights reserved

Privacy Policy

Cookie Policy

Multi colour gradient with abstract wave form

© 2025 Nuclide Therapeutics, All rights reserved

Privacy Policy

Cookie Policy

Create a free website with Framer, the website builder loved by startups, designers and agencies.